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Aims. To evaluate the applicability of the Latent Class Analysis (LCA) and accuracy of transient elastography (TE), aspartate-to-
platelet-ratio-index (APRI), enhanced liver fibrosis (ELF), and liver biopsy (LB) for liver fibrosis assessment in a model without
a gold standard. Methods. Significant fibrosis was defined as TE ≥ 7.1 kPa, APRI ≥ 1.5, ELF ≥ 9.37, or LB METAVIR 𝐹 ≥ 2.
Cirrhosis was defined as TE ≥ 12.5 kPa, APRI ≥ 2.0, ELF ≥ 10.31, or LB as METAVIR 𝐹 = 4. Results. 117 patients with chronic
hepatitis C were included. In the LCA, for significant fibrosis the sensitivities and specificities (95% CI) were 0.92 (0.86–0.98) and
0.79 (0.72–0.86) for TE; 0.47 (0.40–0.54) and 0.99 (0.95–1.00) for APRI; 0.81 (0.74–0.88) and 0.78 (0.71–0.85) for ELF; and 0.86
(0.68–1.00) and 0.91 (0.79–1.00) for LB. For cirrhosis, the sensitivities and specificities were 0.92 (0.76–1.00) and 0.94 (0.91–0.97)
for TE; 0.57 (0.37–0.77) and 0.97 (0.93–1.00) for APRI; 0.94 (0.84–1.00) and 0.88 (0.82–0.94) for ELF; and 0.30 (0.12–0.48) and
1.00 for LB. Conclusion. LCA was useful to evaluate accuracy of methods for liver fibrosis staging. Sensitivities and specificities of
noninvasive methods were increased in LCA compared to the use of LB as the gold standard.
1. Introduction
Chronic hepatitis C remains a major public health issue
representing one of the leading causes of cirrhosis worldwide
[1].The correct determination of liver fibrosis stage has impli-
cations for prognostic, therapeutic, andmonitoring purposes
[2] and the eradication of hepatitis C virus (HCV) has been
associated with lower rates of liver-related complications
[3]. Serological biomarkers, such as FibroTest, FibroMeter,
aspartate-to-platelet-ratio-index (APRI), and enhanced liver
fibrosis (ELF), or imagingmethods, such as transient elastog-
raphy (TE), have been recommended to stage liver fibrosis in
chronic hepatitis C [4]. TE has been described as an accurate
method for fibrosis assessment in HIV/HCV coinfected
patients [5, 6]. Platelet count and liver stiffness measurement
by TE has been validated to predict large gastroesophageal
varices in patients with compensated advanced chronic liver
disease [7]. The high efficacy of direct-acting antiviral drugs
(DAAs) has revolutionized the management of patients
with chronic hepatitis C. However, detection of compensate
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cirrhosis leads to screening for hepatocellular carcinoma and
might change the choice of therapeutic regimen for HCV
eradication [8]. Most of noninvasive methods for fibrosis
assessment have been developed and validated using liver
biopsy as a reference.However, the diagnostic performance of
liver biopsy has been challenged by the length of the liver
specimen [9], sampling error [10], and intraobserver vari-
ability [11]. Therefore, the diagnostic accuracy of noninvasive
methods might have been hampered since liver biopsy might
not be a perfect gold standard [12].
Latent Class Analysis (LCA) is a mathematical modeling
currently applied in qualitative social research to evaluate the
accuracy of tests in the lack of a gold standard [13]. In this
methodology, a reference standard is constructed based on
the combination of observed and estimated tests results from
each patient [14]. A potential limitation might be that this
combination might not fit the data, which may be due either
to nonindependence between the tests (dependency) or to
variability of the disease definition (within-class heterogene-
ity). In addition, LCA assumes that liver biopsy is binary or
dichotomy, whereas fibrosis staging uses a five-stage ordinal
scale (from 𝐹0 to 𝐹4). So far, this methodology has been used
in very few studies in hepatology [12, 15, 16]. The aims of the
study were (i) to evaluate the applicability of the LCAmodels
in patients with chronic hepatitis C and (ii) to estimate the
sensitivities and specificities of TE, APRI, ELF, and liver
biopsy for fibrosis assessment in an approach without a gold
standard.
2. Material and Methods
2.1. Study Design. Patients with chronic hepatitis C from two
centers in Rio de Janeiro (University of the State of Rio de
Janeiro and Bonsucesso Federal Hospital) were prospective
enrolled from April 2011 to July 2012 for this cross-sectional
study. Patients with chronic hepatitis C, characterized by the
presence of HCV-RNA in blood serum, older than 18 years
were included. The exclusion criteria were hepatitis B or
human deficiency virus coinfection, self-reported excessive
alcohol intake (>40 g/day in men and >20 g/day in women),
chronic kidney disease, LB specimenswith less than six portal
tracts, and unreliable LSM.
Liver fibrosis staging was classified according to the
METAVIR scoring [17] and significant fibrosis and cirrhosis
were defined as fibrosis stage 𝐹 ≥ 2 and 𝐹 = 4, respectively.
Noninvasive tests were performed within 3 months from the
date of liver biopsy. The study protocol was conducted in
accordance with Helsinki Declaration and was approved by
the local ethics committees. All patients signed an informed
consent upon enrollment in the study.
2.2. Transient Elastography (TE). TE was performed with M
probe of FibroScan (EchoSens, Paris, France) by an experi-
mented operator (>500 exams) blinded to biomarkers results,
following a validated procedure [13]. TE was considered
unreliable in presence of any of the following criteria: (i) <10
successful measurements; (ii) an interquartile range (IQR)
higher than 30% of the median value; and (iii) a success rate,
considered as the ratio between the number of valid and total
measures, lower than 60% [18]. Liver stiffness was considered
as the median of all valid measurements and fibrosis staging
was converted to the METAVIR scoring system as proposed
by Caste´ra et al. [19]: <7.1 as 𝐹0𝐹1; 7.1–9.4 as 𝐹2; 9.5–12.4 as
𝐹3; and >12.4 kPa as 𝐹4.
2.3. Serological Biomarkers. Serum alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) were measured
by enzymatic assay (ADVIA 1200, Siemens, IL, USA). The
upper limit of normal (ULN) of aminotransferases values was
55 IU/L and 34 IU/L for ALT and AST, respectively. APRI
was calculated according to the following formula: AST level
(/ULN)/platelets count (109/L)∗ 100. Liver fibrosis, estimated
by APRI, was converted to the METAVIR scoring system as
proposed by Wai et al. [20]: ≥1.5 as 𝐹 ≥ 2 and ≥2.0 as
𝐹 = 4. Calculation of ELF was performed in a frozen serum
(−70∘C) that was collected in the same day of TE. Serum
amino-terminal propeptide of type III procollagen (PII-
INP), hyaluronic acid (HA), and tissue inhibitor of matrix
metalloproteinases-1 (TIMP-1) were measured in a random
access automated clinical immunochemistry analyzer that
performs magnetic separation enzyme immunoassay tests
(ADVIA Centaur; Siemens Healthcare Diagnostics, Tarry-
town, NY). The ELF score was calculated using the algo-
rithm recommended by the manufacturer (Siemens, NY,
USA): ELF = 2.278 + 0.851 ln(HA) + 0.751 ln(PIIINP) +
0.394 ln(TIMP-1). Liver fibrosis, estimated by ELF, was con-
verted to the METAVIR scoring system as proposed by
Fernandes et al. [21]: >9.37 as 𝐹 ≥ 2 and >10.31 as 𝐹 = 4.
2.4. Liver Biopsy. Percutaneous liver biopsieswere performed
under local anesthesia (FFF) using a 16-G Menghini needle
guided by ultrasound as a day-clinic hospitalization. All sam-
ples were fixed in a 10% neutral-buffered formalin solution
and cut in 5mm thick sections. Routinely, haematoxylin
and eosin, Masson’s trichrome, and reticulin stains were per-
formed. Biopsies were classified using the METAVIR scoring
system [17] by the same experienced pathologist (FC), who
was blinded to clinical characteristics and noninvasive tests
results.
2.5. Latent Class Analysis (LCA). LCA is a mathematical
modeling that estimates diagnostic accuracy of tests in a
scenario where there is no gold standard.The disease status of
an individual can be considered as a categorical latent variable
such as “disease” or “no disease,” which are named “latent
classes.” Through a mathematical method named standard
maximum likelihood, the modeling aims to obtain a unique
solution for constructing a reference standard. Therefore,
sensitivities and specificities for each test can be estimated.
In addition, the assumption of conditional independence
among tests must be respected and data must fit into the
model (likelihood ratio goodness-of-fit value [likelihood
squared (𝐿2)] significance >0.05) [22].
In the present study, the LCA models were constructed
upon four conditionally independents tests: APRI, ELF, TE,
and liver biopsy. APRI and ELF are both serological biomark-
ers but they include different parameters in the respective
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formulas. Liver fibrosis is estimated by TE considering
the propagation of ultrasound pulses through the hepatic
parenchyma and liver biopsy stages fibrosis is based on
histological analysis by a semiquantitative score. Two latent
class (2LC) models were fitted, one for presence or absence of
significant fibrosis (METAVIR 𝐹 ≥ 2) and the other for
presence or absence of cirrhosis (METAVIR 𝐹 = 4). In each
one of the models, the patient’s status could be classified in
two mutually exclusive groups: presence or absence of “dis-
ease.” Using four tests with a dichotomous result (i.e., positive
or negative) in each patient, there were 16 possible combina-
tions for each clinical endpoint. The likelihood of observing
each pattern of test results was calculated according to the
probability for a positive or negative test. The number of
expected cases estimated by LCA models was compared to
observed cases for each of the patterns of test results.
2.6. Statistical Analysis. Continuous variables were reported
as median [interquartile range, IQR] and discrete variables
were reported as absolute and relative frequency. Nonpara-
metric tests, Mann–Whitney test for quantitative and Fisher’s
exact test for qualitative comparisons, were applied. Signifi-
cance level was determined when 𝑝 ≤ 0.05 assuming two-
tailed tests. In the classical 2 × 2 analysis, the performance of
TE, APRI, and ELF was assessed using the fibrosis stage
obtained by liver biopsy, the classical gold standard. The
standard area under the Receiver Operating Characteristics
(AUROC) curves for diagnosis of significant fibrosis and
cirrhosis was estimated by the empirical (nonparametric)
method [23]. In the LCA models, the sensitivities and speci-
ficities of each test, including liver biopsy, were assessed with-
out a gold standard. For estimation of tests performance for
significant fibrosis and cirrhosis by LCA, the 2LC model
that assumed the conditional independence among tests was
compared to models with direct effect between tests. The
model that better fits for LCA was chosen based on the
following criteria: the 𝑝 value of the likelihood squared (𝐿2)
had to be greater than 0.05 and the Bayesian information
criterion (BIC) had to be the smallest among all competing
models. Statistical analyses were performed using STATA
statistical package for Windows (2012; StataCorp LP, College
Station, TX, USA) and LEM (log-linear event history analysis
with missing data, version 1.0 (Tilburg, Netherlands)).
3. Results
Among 131 eligible patients with chronic hepatitis C, 117
patients [34% male gender, median (IQR) age of 55 (48–62)
years, and BMI of 26 (24–30) Kg/m2] were included. Patients
were excluded due to inadequate liver specimen (less than 6
portal tracts) (𝑛 = 11) or unreliable TE (𝑛 = 3). Serological
biomarkers, APRI and ELF, were reliable in all patients.
According to liver biopsy, the prevalence of significant fibro-
sis and cirrhosis was 46% (𝑛 = 54) and 7% (𝑛 = 8),
respectively. Table 1 summarizes clinical and demographic
characteristics of included patients.
3.1. Classical (2 × 2) Analysis Using Liver Biopsy as a Gold
Standard. Using liver biopsy as reference, for diagnosis of
Table 1: Baseline characteristics of included patients.
Patients (𝑛 = 117)
Male gender 40 (34)
Age, years 55 [48–62]
BMI, kg/m2 26 [24–30]
ALT, U/L 57 [38–110]
AST, U/L 49 [34–81]
Alkaline phosphatases, U/L 76 [62–99]
GGT, U/L 67 [37–129]
Platelets, ×109/L 212 [174–260]
Noninvasive methods
Transient elastography, kPa 8.3 [6.4–13.6]
𝐹 ≥ 2, TE ≥ 7.1 kPa 65 (56)
𝐹 = 4, TE ≥ 12.5 kPa 30 (26)
APRI 0.68 [0.43–1.37]
𝐹 ≥ 2, APRI ≥ 1.5 27 (23)
𝐹 = 4, APRI ≥ 2.0 18 (15)
ELF 9.39 [8.70–10.49]
𝐹 ≥ 2, ELF ≥ 9.37 59 (50)
𝐹 = 4, ELF ≥ 10.31 36 (31)
Liver biopsy
Specimen length, mm 20 [10–30]
Portal tracts, 𝑛 10 [8–12]
Fibrosis, METAVIR
𝐹0𝐹1 63 (54)
𝐹2 35 (30)
𝐹3 11 (9)
𝐹4 8 (7)
Data expressed as median [interquartile range] or absolute (%). ALT, ala-
nine transaminase; APRI, aspartate-to-platelet-ratio-index; AST, aspartate
transaminase; BMI, body mass index; ELF, enhanced liver fibrosis; GGT,
gamma-glutamyltransferase; TE, transient elastography. Caste´ra et al. [19],
Wai et al. [20], and Fernandes et al. [21] cut-offs were used for fibrosis staging
based on transient elastography, APRI, and ELF, respectively.
significant fibrosis the diagnostic performance [AUROC
(95% CI)] of TE, APRI, and ELF was 0.874 (0.811–0.937),
0.810 (0.732–0.887), and 0.807 (0.725–0.889), respectively. In
addition, the performance [AUROC (95% CI)] of TE,
APRI, and ELF for cirrhosis was 0.942 (0.890–0.993), 0.767
(0.585–0.948), and 0.783 (0.555–1.000), respectively. Sensitiv-
ities, specificities, and positive likelihood ratio of noninvasive
methods are summarized in Table 2.
3.2. Latent Class Analysis without a Gold Standard. The 2LC
model that respected the conditional independence among 4
tests (i.e., without direct effect between tests) was the model
that better fitted data for LCA.Thismodel presented the lower
BIC among the competitive models and a nonsignificant
𝐿2 𝑝 value for diagnosis of significant fibrosis and cirrhosis
(Table 3). The observed and estimated patient’s distribution
according to the 4 tests results for diagnosis of significant
fibrosis and cirrhosis are described in Table 4. The tests were
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Table 2: Performance of tests for diagnosis of significant fibrosis (𝐹 ≥ 2) and cirrhosis (𝐹 = 4) as estimated by classical 2 × 2 analysis (liver
biopsy as gold standard) and Latent Class Analysis (without gold standard) considering the model that better fitted data (2LC).
Sensitivity
(95% CI)
Specificity
(95% CI) Positive LR Negative LR
Classical 2 × 2 LCA Classical 2 × 2 LCA
Significant fibrosis (F ≥ 2)
TE 0.87(0.78–0.96)
0.92
(0.86–0.98)
0.71
(0.60–0.82)
0.79
(0.72–0.86) 3.1 0.2
APRI 0.41(0.27–0.55)
0.47
(0.40–0.54)
0.92
(0.89–0.95)
0.99
(0.95–1.00) 5.1 0.6
ELF 0.78(0.67–0.89)
0.81
(0.74–0.88)
0.73
(0.62–0.84)
0.78
(0.71–0.85) 2.9 0.3
Liver biopsy 1.00∗ 0.86(0.68–1.00) 1.00
∗ 0.91
(0.79–1.00) — —
Cirrhosis (F = 4)
TE 1.00 0.92(0.76–1.00)
0.80
(0.71–0.89)
0.94
(0.91–0.97) 4.5 <0.1
APRI 0.50(0.16–0.84)
0.57
(0.37–0.77)
0.87
(0.81–0.93)
0.97
(0.93–1.00) 3.9 0.6
ELF 0.88(0.68–1.00)
0.94
(0.84–1.00)
0.73
(0.64–0.82)
0.88
(0.82–0.94) 3.3 0.2
Liver biopsy 1.00∗ 0.30(0.12–0.48) 1.00
∗ 1.00 — —
∗Gold standard by definition. 2LC, two latent class; TE, transient elastography; APRI, aspartate-to-platelet-ratio-index; ELF, enhanced liver fibrosis; CI,
confidence interval; LCA, Latent Class Analysis; LR, likelihood ratio; AUROC, area under the receiver operator curve. Positive LR and AUROCwere calculated
by classical analysis using liver biopsy as gold standard. Models that data better fitted (2LC) for diagnosis of significant fibrosis [𝐿2 of 9.9504 (𝑝 value =
0.1268)/Bayesian information criteria = −18.6226] and cirrhosis [𝐿2 of 5.6494 (𝑝 value = 0.4636)/Bayesian information criteria = −22.9237] were considered
for Latent Class Analysis.
Table 3: Competitive comparison of latent classes models for assessment of liver fibrosis by noninvasive methods [TE, APRI, and ELF] and
liver biopsy.
Model Model specification Significant fibrosis (𝐹 ≥ 2)
Cirrhosis
(𝐹 = 4)
𝐿2 (𝑝 value) BIC 𝐿2 (𝑝 value)
2LC {X,TE | X,APRI | X,ELF | X, LB | X} 9.9504 (0.1268) −18.6226 5.6494 (0.4636)
2LC with direct effect between TE and
APRI {X,TE APRI | X,ELF | X, LB | X} 7.9601 (0.0931) −11.0886 4.7289 (0.3163)
2LC with direct effect between TE and
ELF {X,TE ELF | X,APRI | X, LB | X} 7.9397 (0.0938) −11.1090 5.4854 (0.2410)
2LC with direct effect between APRI and
ELF {X,TE | X,APRI ELF | X, LB | X} 6.2539 (0.1810) −12.7948 0.1466 (0.9988)
LC, latent class; 𝐿2, likelihood squared; BIC, Bayesian information criterion; TE, transient elastography; APRI, aspartate-to-platelet-ratio-index; ELF, enhanced
liver fibrosis. 2LC was the model that data better fits for estimation of significant fibrosis and cirrhosis.
perfectly concordant in 54 (46%) patients (all positive in 20
and all negative in 34 patients) for diagnosis of significant
fibrosis and in 77 (66%) patients (all positive in 4 and all
negative in 73 patients) for cirrhosis diagnosis.
For diagnosis of significant fibrosis, the sensitivities (95%
CI) were 0.92 (0.86–0.98), 0.47 (0.40–0.54), 0.81 (0.74–0.88),
and 0.86 (0.68–1.00) for TE, APRI, ELF, and liver biopsy,
respectively. In addition, specificities (95% CI) were 0.79
(0.72–0.86), 0.99 (0.95–1.00), 0.78 (0.71–0.85), and 0.91
(0.79–1.00) for TE, APRI, ELF, and liver biopsy, respec-
tively. For cirrhosis, the sensitivities were 0.92 (0.76–1.00),
0.57 (0.37–0.77), 0.94 (0.84–1.00), and 0.30 (0.12–0.48); the
specificities were 0.94 (0.91–0.97), 0.97 (0.93–1.00), 0.88
(0.82–0.94), and 1.00 for TE, APRI, ELF, and liver biopsy,
respectively (Table 2).
Noninvasive methods performed better when analyzed
by LCA in comparison to the classical analysis, using liver
biopsy as a reference. For the cirrhosis diagnosis, sensitivity
of liver biopsy was reduced and its specificity was similar in
LCA compared to classical analysis when liver biopsy was the
gold standard (i.e., sensitivity and specificity = 1.00) (Table 2).
4. Discussion
This study highlighted the reliability of LCA for assessment of
liver fibrosis in a scenario without a gold standard. Sensitivi-
ties and specificities of noninvasive methods (APRI, ELF, and
TE) were higher in LCA models than when liver biopsy was
used as reference. Despite having a satisfactory specificity,
the sensitivity of liver biopsy was fair for diagnosis of
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Table 4: Observed and estimated frequencies and standardized residual for 16 combinations estimated by the Latent Class Analysis (LCA)
model that better fits data (2LC) for diagnosis of significant fibrosis (𝐹 ≥ 2)and cirrhosis (𝐹 = 4).
TE APRI ELF LB Significant fibrosis (𝐹 ≥ 2) Cirrhosis (𝐹4)
Observed Estimated Standardized residual Observed Estimated
1 1 1 1 20 17.158 0.686 4 3.973
1 1 1 0 2 2.790 −0.473 10 9.516
1 1 0 1 1 3.969 −1.490 0 0.236
1 1 0 0 2 0.706 1.540 0 0.688
1 0 1 1 18 19.618 −0.365 3 2.956
1 0 1 0 4 5.626 −0.686 7 7.642
1 0 0 1 8 5.347 1.147 1 0.176
1 0 0 0 10 9.787 0.068 5 4.813
0 1 1 1 1 1.429 −0.359 0 0.356
0 1 1 0 1 0.297 1.288 2 1.119
0 1 0 0 0 0.352 −0.594 0 0.021
0 1 0 1 0 0.299 −0.547 2 2.090
0 0 1 1 3 2.503 0.314 0 0.265
0 0 1 0 10 9.579 0.136 10 10.173
0 0 0 1 3 3.625 −0.328 0 0.016
0 0 0 0 34 33.915 0.015 73 72.960
2LC, two latent class; TE, transient elastography; APRI, aspartate-to-platelet-ratio-index; ELF, enhanced liver fibrosis; LB, liver biopsy. 0, negative; 1, positive.
Latent Class Analysis consideredmodels that data better fitted for diagnosis of significant fibrosis [𝐿2 of 9.9504 (𝑝 value = 0.1268)/Bayesian information criteria
= −18.6226] and cirrhosis [𝐿2 of 5.6494 (𝑝 value = 0.4636)/Bayesian information criteria = −22.9237].
cirrhosis in LCAmodel.These results are in concordancewith
the hypothesis that liver biopsy might not be a perfect gold
standard.
Serological biomarkers and new imaging technologies
for liver fibrosis assessment have been developed in the last
decade [24].Overall, noninvasivemethods for fibrosis staging
have been validated using liver biopsy and the reference.
However, liver biopsy has been challenged by potential
adverse events and sampling error [10, 25]. Therefore, alter-
native methodologies to validate noninvasive markers for
fibrosis assessment without the need of liver biopsy must be
implemented and validated. LCA has been described as an
accurate mathematical model to evaluate the performance of
tests in the absence of gold standard [26].
Using liver biopsy as the reference, we reported an
accuracy of TE, APRI, and ELF for significant fibrosis and cir-
rhosis similar to those described in previous studies [27–29].
Positive and negative likelihood ratios reported in our study
were fair and represented a slight effect on posttest probability
of presence of significant fibrosis or cirrhosis (Table 2).
However, LR+ values were similar to previously published
[30] and the low LR− (<0.1) of TE for diagnosis of cirrhosis
confirmed that this method might be used for exclusion of
this condition in HCV patients. Considering the approach
by LCA, the sensitivity of noninvasive methods for diagnosis
of significant fibrosis increased when compared to classical
analysis (Table 2). Similarly, better results were also reported
for TE and FibroTest by authors that used the same math-
ematical model [12]. In the present study, regardless of the
type of methodology used (classical analysis or LCA), TE and
APRI were the most sensitive and specific tests for diagnosis
of significant fibrosis, respectively (Table 2). In a sensitivity
analysis when considering the dual cut-off points proposed
for APRI (i.e., ≥0.5 as 𝐹 ≥ 2 and ≥1.0 as 𝐹 = 4) [20], we
reported similar results for the accuracy of TE, ELF, and liver
biopsy (Supplementary Table 1 in Supplementary Material
available online at https://doi.org/10.1155/2017/8252980).
For diagnosis of significant fibrosis, the sensitivity and
specificity of liver biopsy decreased in LCA yielding 14%
of false negative and 9% of false-positive results. More
importantly, we had a substantial decrease in the sensitivity of
liver biopsy for cirrhosis diagnosis [0.30 (95% CI 0.12–0.48)].
Despite a decrease in sensitivity, the specificity of liver biopsy
to detect significant fibrosis or cirrhosis did not change when
LCA was applied. These results were aligned with previous
studies: Poynard et al. reported a decrease in sensitivity of
liver biopsy from 1.00 (as a gold standard) to 0.51 when LCA
was applied [12]. We acknowledge that both studies included
different sample size and potential distinct populations. We
mostly included female patients with mild fibrosis (54%)
and had a low prevalence of cirrhosis (7%). The French
study included a more homogenous population, mostly male
gender with 15% of cirrhotic patients [12]. In addition, the
impact of prevalence of liver fibrosis stages in diagnostic
performance of biomarkers based on the spectrumbiasmight
lead to discordance in conclusions for test accuracy [31, 32].
The decrease of sensitivity of liver biopsy in LCA com-
pared to classical analysis might be a reflex of the limitations
of liver biopsy. Previous studies reported a considerable
discrepancy between liver biopsies performed in both hepatic
lobes of the same patient [33], as well as a significant under-
estimation of severity of liver disease by reduction in the liver
specimen length [9]. Bedossa et al. have described that even
the “classical 20mm length” sample could misclassify liver
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fibrosis in a quarter of patients [10]. Mehta et al. estimated
the magnitude of the bias of diagnostic performance of
noninvasive methods due to liver biopsy limitations [34].
The diagnostic performance of a noninvasive method
might never reach the maximal AUROC value using liver
biopsy as the reference due to gold standard limitations [25].
Since noninvasive methods have been validated using his-
tology as the reference, these tests might replicate the false
negative and positive of liver biopsy, biasing its diagnostic
accuracy. As a practical implication of LCA, the present
study confirmed that wemust move forward on estimation of
diagnostic performance of noninvasive methods for fibrosis
staging using methodologies without gold standard.
Noninvasive methods have also important limitations
that should be considered. TE performed by theMprobemay
be unreliable in 20% of patients [35] and this method might
have a nonnegligible inter- and intraobserver variability
[36, 37]. In addition, liver fibrosis staging by TE might be
impacted by presence of necroinflammatory activity, obesity,
extrahepatic cholestasis, hepatic congestion, and nonfasting
status [38]. In the present study, false-positive rates were
higher in obese patients (𝑛 = 30) compared to thosewith BMI
< 30Kg/m2 (Supplementary Table 2). ELF includes serum
markers involved in the synthesis and breakdown of the
extracellular matrix that might be elevated in other systemic
diseases not related to liver fibrosis [39]. Finally, APRI has
a considerable variability due to laboratory upper limit for
normalAST and can be overestimated in presence of necroin-
flammatory activity due to utilization of transaminases in its
formula [40].
We acknowledge that our limited sample (𝑛 = 117)
with a low prevalence of cirrhosis (7%) and single blinded
histological analysis were the major limitations of our study.
We included treatment-naı¨ve patients with chronic hepatitis
C with fibrosis staging for therapeutic decision. The relative
low prevalence of cirrhotic patients impacted both method-
ologies (classical analysis and LCA) to access diagnostic
accuracy of noninvasivemethods. In addition, Rousselet et al.
have demonstrated that a single pathologist specialized in
liver histology can accurately stage fibrosis in a liver specimen
with a good quality [41]. In the present study, the histological
analysis was performed by an experimented liver specialized
pathologist (FC) in a specimen with a median of 20mm and
10 portal tracts. We are aware that LCA models might not be
considered per se as a new gold standard for estimation of
sensitivities and specificities of noninvasive tests for fibrosis
assessment. It should be interpreted as an estimator of
accuracy of diagnostic tests with appropriate consideration of
limits and strengths [42].
The major strength of this study relies on the fact that
we respect the criteria for LCA and that data fitted very well
in the model without colinearity between noninvasive tests
(2LC model). In our study, latent class rules were strictly
respected using four conditionally independent tests into the
analysis. In addition, the 2LC model without direct effect
between tests was the model that better fitted the data (lower
BIC among competitive models and a nonsignificant 𝐿2𝑝
value) (Table 3). In a sensitivity analysis, similar results for
accuracy of the four tests were observed inmodels with direct
effect between noninvasive methods (Supplementary Table
3).
5. Conclusion
The application of LCA method was useful to evaluate
diagnostic performance of noninvasive methods for liver
fibrosis assessment. Sensitivities and specificities of noninva-
sive methods were increased in LCA compared to the use of
liver biopsy as the gold standard. These results reinforced
that liver biopsy might be an imperfect reference and that
mathematical models without a gold standard should be
considered in future studies for validation of noninvasive tests
for liver fibrosis staging.
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